Physician profile
Denise Odea
NPI 1568438067
$3,444.47
in general payments reported to CMS, 2019-2025
12 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $575 · 2023: $351 · 2024: $1,103 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,594.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,212.78 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $436.96 | 2021-2024 | Lynparza |
| Abbvie INC. | $409.00 | 2024-2025 | |
| Janssen Biotech, INC. | $286.40 | 2024-2025 | Rybrevant, Carvykti, Darzalex |
| Exelixis INC. | $204.77 | 2023-2024 | |
| Gt Medical Technologies, INC | $151.63 | 2023 | Gammatile |
| Incyte Corporation | $140.00 | 2021 | |
| Pfizer INC. | $125.00 | 2024 | |
| Springworks Therapeutics, INC. | $124.39 | 2025 | |
| Genmab U.S., INC. | $122.72 | 2022 | |
| G1 Therapeutics, INC. | $119.12 | 2022 | |
| Stemline Therapeutics INC. | $111.70 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Odea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.